Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W LUTZ

Showing results (481-490 of 538) with videos related to

Pageof 54
Sort By:
British Journal of Cancer|July 1, 1984
The Edinburgh randomised trial of screening for breast cancer: description of methodM M Roberts, F E Alexander, T J Anderson, et al.
Neuromuscular Disorders : NMD|October 10, 2013
Polymorphism in the TOMM40 gene modifies the risk of developing sporadic inclusion body myositis and the age of onset of symptomsF L Mastaglia, A Rojana-udomsart, I James, et al.
Journal of Alzheimer'S Disease : JAD|July 17, 2023
The APOE-TOMM40 Humanized Mouse Model: Characterization of Age, Sex, and PolyT Variant Effects on Gene ExpressionWilliam K Gottschalk, Scott Mahon, Dellila Hodgson, et al.
Journal of Medicinal Chemistry|July 1, 1991
Design, synthesis, and pharmacological evaluation of ultrashort- to long-acting opioid analgeticsP L Feldman, M K James, M F Brackeen, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 1, 1994
A pharmacodynamic model to investigate the structure-activity profile of a series of novel opioid analgesicsM W Lutz, P H Morgan, M K James, et al.
The Pharmacogenomics Journal|December 24, 2009
A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's diseaseA D Roses, M W Lutz, H Amrine-Madsen, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|August 7, 2012
A homopolymer polymorphism in the TOMM40 gene contributes to cognitive performance in agingKathleen M Hayden, Jill M McEvoy, Colton Linnertz, et al.
Current Opinion in Pharmacology|February 26, 2014
New applications of disease genetics and pharmacogenetics to drug developmentAllen D Roses, Ann M Saunders, Michael W Lutz, et al.
Neurology. Clinical Practice|May 11, 2026
Evaluating the Duke Iterative Cognitive Examination Against the Montreal Cognitive Assessment: Validity and Clinical UtilityChristine Park, Thomas J Farrer, Jill Z Stuart, et al.
Neurology|January 22, 2017
<i>TOMM40</i>'523 variant and cognitive decline in older persons with <i>APOE</i> ε3/3 genotypeLei Yu, Michael W Lutz, Robert S Wilson, et al.
Pageof 54

Showing results (481-490 of 538) with videos related to

Sort By:
Pageof 54
British Journal of Cancer|July 1, 1984
The Edinburgh randomised trial of screening for breast cancer: description of methodM M Roberts, F E Alexander, T J Anderson, et al.
Neuromuscular Disorders : NMD|October 10, 2013
Polymorphism in the TOMM40 gene modifies the risk of developing sporadic inclusion body myositis and the age of onset of symptomsF L Mastaglia, A Rojana-udomsart, I James, et al.
Journal of Alzheimer'S Disease : JAD|July 17, 2023
The APOE-TOMM40 Humanized Mouse Model: Characterization of Age, Sex, and PolyT Variant Effects on Gene ExpressionWilliam K Gottschalk, Scott Mahon, Dellila Hodgson, et al.
Journal of Medicinal Chemistry|July 1, 1991
Design, synthesis, and pharmacological evaluation of ultrashort- to long-acting opioid analgeticsP L Feldman, M K James, M F Brackeen, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 1, 1994
A pharmacodynamic model to investigate the structure-activity profile of a series of novel opioid analgesicsM W Lutz, P H Morgan, M K James, et al.
The Pharmacogenomics Journal|December 24, 2009
A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's diseaseA D Roses, M W Lutz, H Amrine-Madsen, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|August 7, 2012
A homopolymer polymorphism in the TOMM40 gene contributes to cognitive performance in agingKathleen M Hayden, Jill M McEvoy, Colton Linnertz, et al.
Current Opinion in Pharmacology|February 26, 2014
New applications of disease genetics and pharmacogenetics to drug developmentAllen D Roses, Ann M Saunders, Michael W Lutz, et al.
Neurology. Clinical Practice|May 11, 2026
Evaluating the Duke Iterative Cognitive Examination Against the Montreal Cognitive Assessment: Validity and Clinical UtilityChristine Park, Thomas J Farrer, Jill Z Stuart, et al.
Neurology|January 22, 2017
<i>TOMM40</i>'523 variant and cognitive decline in older persons with <i>APOE</i> ε3/3 genotypeLei Yu, Michael W Lutz, Robert S Wilson, et al.
Pageof 54